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Summary  
Gliomas are tumors of the central nervous system (CNS). They are responsible for about 
28% of all central nervous system tumors and for 80% of all malignant brain tumors. The 
most commonly used classification and grading of CNS tumors is the World Health 
organization (WHO) classification: According to the WHO classification, gliomas are 
divided into four grades, from grade I to IV. Furthermore, different grade tumors are 
characterised by different genetic aberrations and phenotypes.  
Tumor and fetal development display a resemblance due to the fast increase in biomass and 
extensive cell migration that characterised both processes. Thus the early embryo and tumors 
may share a common genetic basis. POU domain transcription factors have a critical role in 
embryo development, and reexpression/overexpression of these transcription factors have 
been reported in many cancers. POU3f2 is an intronless member of class III POU domain 
transcription factors. Its expression is confined to the CNS where it is involved in 
differentiation of neuronal and glial cell lineages in the embryo. Re-expression of POU3f2 
has been reported in melanoma cancer by several independent groups. Although POU3f2 
expression in gliomas has been sporadically reported, it has not been systematically 
characterised in a larger panel of gliomas of different grades and histologies. Since 
melanocytes and the main CNS cell types share a common neuroectodermal origin therefore, 
we hypothesized that POU3f2 is expressed in human gliomas. 
In order to assess the expression of POU3f2 in glioma patients, and its possible correlation 
with malignancy grade, 51 formalin fixed paraffin embedded patient biopsies (grade II-IV) 
were stained by immunohistochemistry. Secondly, to confirm IHC results, western blotting 
and qRT-PCR were performed on about 40 human glioma biopsies. In addition, we 
conducted a series of experiments in vitro and in vivo to investigate how POU3f2 impacted 
on various aspects of glioma cell behavior. 
We found that, POU3f2 is expressed in all grades of glioma of both astrocytic and 
oligodendroglial lineages. Moreover, expression was higher in grade IV than grade II 
tumors, whereas over-expression of POU3f2 in the U251cell line increased both glioma cell 
proliferation and colony formation. Conversely, down-regulation of POU3f2 decreased 
colony formation. Finally, over-expression of POU3f2 in the U251cell line promoted tumor 
VI 
 
growth in nude mice, compared to U251 glioma cells with down-regulation of POU3f2 or 
expression of scrambled RNA sequences. 
My plan for future studies will be to expand the present data to include additional glioma cell 
lines. In addition, my goal is to establish which signaling pathway mediates the effects of 
POU3f2.  
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1. Introduction 
1.1 Cancer  
1.1.1 Cancer  
Cancer is characterized by dysregulated and increased cell division resulting from a 
sequential acquisition of DNA changes
1,2
. Thus, cancer has been characterised as a disease of 
the genome since it invariably displays some form of genetic aberration, including mutations 
and chromosomal rearrangements which dictate clinical behavior
3,4
. Typically these changes 
involve oncogenes and tumor suppressors. The oncogenes accelerate cell growth while 
tumor suppressors have the opposite effect. Therefore, gene alterations that increase 
oncogene activity or decrease tumor suppressor activity may promote cell proliferation
5
. 
Generally, one single cell is the origin of the cancer through clonal growth. The resulting 
tumor can invade nearby tissues, and may also spread to other organs
6
. Any part of the body 
can be affected by cancer
6
. In 2012, 8.2 million deaths were attributed to cancer with lung, 
liver, stomach, colorectal and breast cancer being the cause of most cancer deaths in all the 
world
6
. Genetic inheritance is the cause of 5-10% of all the cancers, whereas in 90-95% of 
the cases, environment and lifestyle (cigarette smoking, diet, alcohol, sun exposure, 
pollutants, infections, stress, and obesity) are held responsible. Thus, life style changes may 
be the most effective strategy to reduce the incidence of cancer
7
.  
1.1.2 Cancer - hallmarks  
Cancer is a progressive disease; the normal cell undergoes a multistep process to acquire the 
features of a cancer cell. Six physiologic changes (also called hallmarks) which are necessary 
for malignant growth have been suggested by Hanahan and Weinberg (Fig 1.1.2). Self-
sufficiency in growth signals is the first hallmark; normal cells need mitogenic growth 
signals for proliferation. In many cancers, normal growth signaling is mimicked by 
oncogenes
8,9
. In normal cells, cellular quiescence and tissue homeostasis are maintained by 
various anti-proliferative signals inhibiting growth via transmembrane cell surface receptors. 
Conversely, cancer cells are often insensitive to antigrowth signals (second hallmark)
8
. In 
addition, their ability to evade apoptosis (third hallmark) also increases overall tumor 
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growth
8
, whereas disruption of cell-to-cell signaling and aberrant telomerase expression 
contribute to a limitless replicative potential (fourth hallmark)
8
. Without blood circulation, 
cancer cells grow up to 1-2 mm
3
 in diameter, but for further development (beyond 2mm
3
) 
angiogenesis (fifth hallmark) is necessary for tumor growth
10
, and is mediated by the release 
of vascular endothelial growth factor (VEGF) from the tumor cells. Tissue Invasion and 
Metastasis constitute the sixth hallmark of cancer: If untreated, primary malignant tumors 
will at some point invade nearby tissue and spread to distant sites of the body, which is the 
cause of 90% of cancer-related deaths. Recently, Hanahan et al also proposed that the 
reprograming of energy metabolism could be cited as “Emerging Hallmarks” (Fig 1.1.2)9. 
The energy needed for cell proliferation is for a large part obtained by elevated glycolysis 
and lactate production even under aerobic conditions  (Warburg effect)
9
. Another emerging 
hallmark that has been proposed, is the evasion of immune destruction by cancer cells
9
. 
Genome instability has been seen as an enabling characteristic through random mutations 
and chromosome rearrangement leading to the acquisition of the multiple hallmarks
9
. 
Furthermore, inflammation can have a tumor-promoting role by providing bioactive 
molecules to the tumor microenvironment. Inflammatory changes is often mediated by 
Figure 1.1.2 Hallmarks of cancer. The six hallmarks introduced by Hanahan and Weinberg in 2000. Two 
enabling characteristics and two emerging hallmarks were later proposed (Reprinted with permission).  
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immune cells that supply growth factors, survival factors, proangiogenic factors and matrix-
modifying enzymes
9
. Since these hallmarks are considered necessary for malignant 
transformations, they may also be therapeutic targets. However, cancer cells often respond 
with compensatory changes, and can reduce their dependence on specific hallmarks while 
using others during cancer progression
9
.  
1.1.3 Gliomas- classification, grading and epidemiology  
Gliomas are tumors of the central nervous system (CNS) in which the neoplastic cells 
display a glial phenotype. They account for about 28% of all central nervous system tumors 
and 80% of all malignant brain tumors
11
. The current glioma classification is based on the 
tumor cells’ resemblance to the main glial cell types12,13, whereas tumors are graded on their 
degree of malignancy
14
. This grading is based on histological changes such as the presence 
of nuclear pleomorphism, mitotic activity, endothelial cell proliferation and necrosis
11,15
. 
According to the WHO classification, gliomas are classified from grade I that are considered 
benign to grade IV, the most aggressive tumors
16,5
. Notably, the different grades correlate 
with different prognoses and treatment guidelines are also based on tumor grade
15,17
. The 
classification for astrocytic tumors are shown in table 1.1.3
12,17
. Grade II astrocytoma 
typically display nuclear atypia
18
. Patients with grade II have a 5-year survival rate of 
approximately 50%.
5,11
. Grade III is characterized by nuclear atypia and mitotic activity. 
Patients with grade III tumors survive 2-5 years
5
. Both grade II and III tumors are infiltrative 
in nature
15
 and have a propensity for malignant progression to a higher grade
5,19,20
. GBM is a 
grade IV tumor showing all the traits of grade II-III tumors plus necrosis and vascular 
proliferation
15
, and median survival is 15 months
21,22
. Tumors with none of these features are 
Table 1.1.3 Astrocytoma grading according to the World Health Organization (WHO) classification. 
Modified from WHO classification
5
. 
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grouped as grade I
18
. Grade I is assigned to the more circumscribed pilocytic astrocytoma
15
, 
this tumor is the most common glioma in children with excellent prognosis after tumor 
removal
19,23
.  
The relative frequency of different glioma types is illustrated in figure 1.1.3. Apart from 
astrocytomas other important types of gliomas are oligodendroglioma, mixed 
oligoastrocytoma and ependymoma
11
. Oligodendrogliomas constitute about 6.1% of all 
gliomas
24
. According to the WHO grading system, oligodendrogliomas are divided into 
grade II (oligodendrogliomas) and grade III (anaplastic oligodendrogliomas) tumors. 
Oligodendrogliomas are infiltrative and usually arise in adults, in the age range 50-60 years
5
. 
The mixed oligoastrocytomas have features of both astrocytoma and oligodendroglioma
5,11
. 
Ependymomas are usually slow growing and typically occur in children and young adults. It 
originates from the wall of the cerebral ventricles and spinal canal
5
. 
According to the International Agency for Research On Cancer (IARC), the incidence rate 
(new cases/100 000/year) of brain tumors globally was 3.4 in 2012 (5-years prevalence) with 
3.9 for men and 3.0 for women
25
. The incidence of brain tumors is higher in developed 
Figure 1.1.3 Distribution of Primary Brain and CNS gliomas by histology subtypes. This data was 
collected from 2005 to 2010 in the United States of America
24
. 
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countries than in less developed countries
26
. According to the Central Brain Tumor Registry 
of the United States (CBTRUS) between 2006 to 2010, the incidence rate of glioma was 7.14 
for men and 5.06 for women
24
. The incidence of gliomas is twice as high in Caucasians 
compared to Africans
24
. In addition, the frequency of gliomas is higher in men than 
women
24,27
. Glioblastoma is the most common glioma (54.4% of all gliomas) while 
astrocytoma and glioblastoma are responsible for about 75% of all gliomas (Fig 1.1.3).  
1.1.4 Genetic progression in gliomas 
Gliomas are genetically heterogeneous although some genetic changes are associated with 
histological subtypes or different grades (Fig 1.1.4). Mutations in TP53 and IDH1 are among 
the earliest genetic aberrations in grade II astrocytoma and are also seen in secondary 
glioblastomas
11
. About 25% of grade II astrocytomas however, are not TP53 mutated and 
display other genetic alterations such as gain of chromosome 7q and amplification of 8q
5
.  
Genetically, anaplastic astrocytoma represent an intermediate stage in glioma progression
5
. 
The rate of TP53 mutation is high in anaplastic astrocytomas (53%)
5,28
 as in astrocytomas. 
Other important mutations are IDH1/2 mutation (about 80%)
29
, p16 deletion (~ 30%), RB 
mutation (25%), p19
ARF
 deletion (15%), CDK4 amplification (10%), LOH on chromosome 
10q (30%), LOH on chromosome 19q (~ 40%), LOH on 22q (~ 30%)
5
 (Fig 1.1.4). 
Glioblastoma multiforme (GBM) (grade IV) may develop de novo (primary GBM) or arise 
from a lower grade glioma (secondary GBM). Primary GBMs develop at older age (mean 
age 62 years), while secondary GBMs develop in younger patients (mean age 45 years)
30
. 
Primary and secondary GBMs display both overlapping and distinct genetic changes
28
 (Fig 
1.1.4). LOH of 10q is the most genetic aberration in both primary and secondary GBMs. 
PTEN inactivation and EGFR amplification are the most frequent genetic alterations in 
primary GBMs, while TP53 mutation occurs more frequently in secondary GBMs 
31,32
. The 
MDM2 amplification/overexpression is more common in primary GBMs without a TP53 
mutation, while overexpression of MDM2 mutation in secondary GBMs is about 10% 
28
. 
The rate of LOH on chromosome 19 is higher in secondary GBMs (54%) in comparison to 
primary GBMs (6%)
28
. The incidence of IDH1 mutation in secondary glioblastoma (88%) is 
higher than primary glioblastoma (7%)
33
. These genetic aberrations usually impact on 
changes in receptor tyrosine kinase signaling (88%), the TP53 (87%) and RB pathway 
(78%)
34
.  
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The pilocytic astrocytomas (PAs) display loss of chromosomes 17 or 17p and gain of 8q as 
the most frequent karyotype changes in PAs
35
. Mutation in the P53 gene is also reported in 
0-35% of PAs cases
36
 but it is not indicative of PAs
5
.  
Genetic aberrations in oligodendrogliomas are distinct from those observed in astrocytomas. 
Loss of heterozygosity (LOH) on 19q (50-80%) is the first and LOH of 1p (67%) is the 
second most frequent genetic change in Oligodendogliomas, whereas the rate of TP53 
mutation is low
5
. Anaplastic oligodendrogliomas, display 19q and 1p deletions similarly to 
grade II oligodendroglioma, but often also have deletions of 9p and additional chromosomes  
(4, 6, 10, 11, 15 and 18)
5,37
. IDH1/2 mutations are observed in approximately 65% of 
oligodendroglioma
33,29
. 
1.1.5 Biology of gliomas and its implications for diagnosis, treatment and 
prognosis 
1.1.5.1 General biology of gliomas 
Proliferation: Immunostaining for the proliferation marker Ki-67 show that only 
approximately 4% of tumor cells in gradeII are actively cycling, whereas the fraction is 
usually in the range of 5-10% in anaplastic astrocytomas
5,38
. The rate of Ki-67 expression in 
GBM is even higher, typically 15-20%
5,38
. 
Angiogenesis: Angiogenesis is considered a key event in malignant glioma progression, 
accompanying the transition from grade III to grade IV tumors
39
. Normally, hypoxic 
conditions induce the release of angiogenic factors and down-regulation of anti-angiogenic 
factors
39
. GBMs usually are highly angiogenic, and typically display large dilated and 
malformed. Vessel formation is not present in grade II and III gliomas, although angiogenic 
factors are released in grade III gliomas
39
. 
Invasion: All grade II-IV gliomas are characterised by highly infiltrative growth
40
. 
Typically, glioma cells migrate along the white matter tracts, often to the contralateral 
hemisphere. They also infiltrate the cortex and in the subependymal zone. However, gliomas 
hardly ever metastasise outside the CNS
5,41
.  
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1.1.5.2 Diagnosis 
Diagnosis of glioma is based on clinical symptoms, neuroimaging and histopathological 
examination
5
. Glioma patients typically describe symptoms such as headache, seizure, mood 
and personality changes, vomiting, nausea, epilepsy, memory loss, confusion and visual 
changes
42,43,44,45,46
. These symptoms can either be ascribed to increased intracranial pressure 
or they result from invasion or compression of surrounding structures. MRI is currently the 
preferred method for diagnosing gliomas
47
. On contrast-enhanced T1-weighted MRI images, 
GBMs appear as a hypo-intense lesion surrounded by a contrasting-enhancing ring structure 
representing a disrupted blood-brain-barrier. On T2-weighted images and fluid-attenuated 
inversion recovery (FLAIR), tumors appear hyper-intense
48
. In anaplastic astrocytomas 
(WHO grade III) only modest contrast enhancement is usually observed. Grade II 
astrocytomas do not enhance, and the tumor area appear hypo-intense on T1-weighted 
images and hyper-intensity on T2-weighted images
5
. In patients that cannot undergo MRI, 
CT usually shows the area of contrast enhancement clearly, surrounding a hypo-dense area. 
Lower grade gliomas usually do not enhance and typically present as hypo-dense lesions 
although they can be difficult detect
5
. 
1.1.5.3 Treatment 
The primary treatment for grade III and IV gliomas is usually surgery followed by radio- and 
chemotherapy
49
. In grade II gliomas the primary treatment is most often surgery alone
46
. 
Surgery: The goal of surgery in gliomas is to: (1) provide histological diagnosis, (2) relieve 
intracranial pressure (3) by gross removal of the tumor increase survival time of the 
patients
50
. As much tumor mass as possible is removed without causing neurological 
deficits
51
. Radical removal of gliomas is not possible due to their infiltrative growth. Gross 
total removal however, is correlated with longer survival and better quality of life
52
. In 
patients with pilocytic astrocytoma, surgical resection of the tumor is the first choice of 
treatment, and complete resection of the tumor results in a cure
53
. 
Radiotherapy: Fractionated radiotherapy is routinely administered for grade III and IV 
gliomas after surgery to a total of 54-60 Gray, and has been shown to prolong survival. This 
give in 30 fractions of 1.8-2 Gray over 6 weeks
54
. Patients over 70 years usually receive a 
lower dose due to side-effects
55
. In grade II tumors, with low mitotic labeling index, 
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radiotherapy is usually not given but may be considered with early recurrences or other signs 
of an aggressive disease course
49
.  
Chemotherapy: Temozolomide (TMZ) is now routinely given to patients with grade III and 
IV gliomas and has been shown to prolong survival
54,56
. TMZ is an alkylating agent which is 
administered orally and usually well tolerated
57
. It is given concomitantly with fractionated 
radiotherapy and then adjuvantly in five-days cycles every fourth week for a total of six 
times
58
. TMZ is not routinely administered for grad II gliomas
57
. 
 
Treatment of Oligodendrogliomas: LOH of 1p/19q chromosome has been established as a 
predictive marker for response to chemotherapy, and, Oligodendrogliomas are usually more 
chemosensitive than astrocytomas
59,56
. Both TMZ and PCV (procarbazine, CCNU, 
vincristine) are both in clinical use, and they are considered to be of similar anti-tumor 
efficacy
60,56
. In recent years, various biological therapies have been tested clinically, such as 
tyrosine kinases targeting the EGFR and PDGFR receptors, and inhibitors of mTOR and 
PI3K. However, a survival benefit has not been shown with any of these tratments
61,62
. 
1.1.6 Gliomas from a developmental perspective 
Development of the fetus and tumor growth display a resemblance from a biological and 
molecular perspective
63
. Both processes are accompanied by extensive cell proliferation and 
migration
63
. Furthermore, several studies have shown that genes expressed in the embryo are 
aberrantly expressed in cancers
63,64
. Notably, pluripotent stem cells express the transcription 
factors Oct4, SOX2 and Nanog which are also expressed in gliomas
65,66
. In stem cells, these 
factors are important regulators of potency and self-renewal during development of the fetus. 
It is therefore possible that they have a similar role in gliomas
65
. Moreover, embryonic stem 
cells (ESCs) and gliomas show activation of the same signaling pathways, such as activation 
of the Notch signaling pathway and the Hedgehog signaling pathway
67
.  
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1.2 POU3f2 
1.2.1 The POU class of transcription factors – structure and function 
The process of differentiation is tightly regulated by numerous transcription factors. The 
family of POU transcription factors is divided into six classes in mammalians
68
. In 
mammals, six classes of POU proteins have been described based upon amino acid sequence 
of the POU domain as well as the extent of linker region conservation
68
. Some POU 
transcription factors are expressed in specific cell types whereas others are expressed more 
broadly. They perform different functions such as regulation of house-keeping genes, and 
have a crucial role in the determination of the cells fate
68
. In addition, they are critical to 
neuronal cell function
69
.The POU proteins bind promoters of other genes involved in DNA 
replication and development
68
.The POU domain was first described in 1988
70
 and was 
recognized by comparison of three mammalian transcription regulators, Pit 1, Oct1 and Oct 2 
Figure 1.2.1 General structure of POU-domain. The POU-domain consists of both homeodomain 
(POUH) and POU-specific domain (POUS) which join to each other by flexible linker. The POUH and 
POUS bind to opposite sides of the DNA while are connected to each other by linker. The POUS 
domain binds to the ATGC half site and the POUH domain binds to the AAAT half site
74
. Drawn by 
Per Øystein Sakariassen. 
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with the Unc-86 gene from a nematode cell lineage called Caenorbabditis elegans
69,71,72
. 
POU domains have not been identified in fungi or plants
71
. The POU domain proteins are 
characterized by a conserved region that contains 150-160 amino acids
73
. The POU domain 
is bipartite and consists of two POU sub-domains, the POU- specific (POUs) domain at the 
N-terminal which consists of 75-82 amino acids, and the POU-homeo (POUH) domain at the 
C-terminal which consists of 60 amino acids (Fig 1.2.1). These subdomains are connected to 
each other by a lesser conserved linker region of 15 to 56 amino acids in length
69,74
. The 
POUS and POUH domains both have a helix-turn-helix (HTH) motif and are able to 
recognize and bind specific DNA sequences independently
71
. POUS consists of four α-helices 
of which α1 and α4 stabilize the HTH motif whereas α3-helix is a DNA-recognition helix. 
The POUH consists of three α-helices, in which α1 stabilizes the HTH while α3 is 
responsible for recognition of a specific DNA-sequence
71,73 
(Fig 1.2.1).  
The isolated POUS bind to the specific sequences of DNA with very low affinity while the 
POUH binds DNA with moderate affinity
75
. The POU domain transcription factors require 
both the POUS and POUH in order to bind to the specific site of DNA with high affinity
74
. 
The DNA sequence recognized by the POU domain is the 5´-ATGCAAAT-3´ octameric 
sequence. The protein crystallography of the Oct1 protein shows that both the POUS and 
POUH domains bind to the major groove of the DNA strand, but on the opposite sides of the 
DNA helix. The POUS binds to the 5´-ATGC and the POUH binds to the 3´-AAAT. The 
POU transcription factors are able to combine to other co-activators, co-repressors or other 
transcription factors from the same or other families in order to perform their activities
68
. 
The linker gives flexibility leading to differences in orientation of the half-site sequences that 
are bound by the POUS and POUH domains.  
1.2.2 Regional expression patterns of POU transcription factors 
The POU factors display different spatiotemporal expression patterns and execute various 
biological functions. Some members of the POU family are expressed ubiquitously, while 
others show a restricted spatial expression with a more limited function
69
 (Table 1.2.3). They 
are expressed at different embryonal stages, and have critical roles during development. In 
adults, the POU transcription factors are generally not expressed, or at only low levels, 
except Oct1 (member of class II) which is expressed in many cell types
72
 (Table 1.2.3). The 
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abundant expression of Oct1 and the presence of an octamer motif in the promoters of 
housekeeping genes suggest that Oct1 is a constitutive housekeeping transcription factor
76
. 
Oct4 (member of class V) and Oct6 (member of class III) have been identified in embryonic 
stem cells
69
. Oct4 is one of the earliest genes expressed from the zygote genome which is 
necessary for the generation of pluripotent embryonic stem cells
68
 (Table 1.2.3). Oct4 
specifies cell fate while its expression decreases after differentiation
77
. Cell fate decisions are 
highly sensitive to changes in Oct4 expression. Oct4 has a pivotal role in the ESCs fate, and 
they maintain the pluripotent potential of stem cells only when Oct4 is expressed in the 
physiological range. Conversely two fold overexpression triggers ESC differentiation into 
primitive endoderm and mesoderm, whereas a downregulation of Oct4 induces ESCs to 
differentiate into trophoblasts
68,77
. In adults, Oct4 mRNA expression is detected in the 
ovaries and testes
78,69 
(Table 1.2.3). In addition, Oct4 mRNA and protein are observed in the 
oocyte but not in spermatocytes
79,80
. Initially, Oct4 is expressed throughout the blastomere, 
while it subsequently is confined to the inner cell mass (ICM) of the blastocyst. 
Oct6 is expressed in early embryogenesis, similarly to Oct4 in the totipotent and pluripotent 
stem cells of the pre-gastrulation embryo. It is down-regulated during later development, 
although it remains expressed in specific developing neurons and is found in the adult brain 
and testes
81
 (Table 1.2.3). 
A significant number of the POU domain proteins, such as Tst1/Oct-6/SCIP, Pit1, Oct1, 
Oct2, Brn1, Brn2 (POU3f2), Brn4, Brn3a, Brn3b, and Brn5 are expressed primarily or 
exclusively in the nervous system
69,68,81
. The Pit1 transcription factor is a member of the 
Class I POU transcription factors (Table 1.2.3) and regulates pituitary development. Pit1 is 
necessary for final development of thyrotropes (TSH expression), lactotropes (prolactin 
(PRL) expression) and somatotropes (growth hormone (GH) expression)
76
. Animals that are 
not able to express Pit1, have hypoplastic pituitaries and lack somatotropes, lactotropes, and 
thyrotropes
74
.  
Oct2 is member of the class II POU domain which is widely expressed in neurons during 
embryonal development (Table 1.2.3). In adults, Oct2 expression is confined to the 
suprachiasmatic and medial mammillary nuclei, hippocampus, olfactory tract, olfactory bulb, 
lymphoid cells, testes and thymus
69,79
.  
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Brn1, Brn2 (POU3f2), Brn4 and Tst-1/Pou3f1/SCIP (OCT6) are four intronless mammalian 
class III POU genes
74,82
 (Table 1.2.3). Brn1, POU3f2 and Brn4 are expressed extensively in 
the nervous system at day 10 to 11. By day 14, Brn1 and POU3f2 are expressed in four 
separate regions in the hypothalamus (preoptic, anterior, ventromedial, and mammillary 
nuclei) while POU3f2 and Brn4 are co-localized in the paraventricular and supraoptic 
neurons
79
. Tst1/Pou3f1/SCIP is expressed in oligodendrocyte precursors and developing 
Schwann cells, and is responsible for myelination in the CNS and PNS.  
Class IV POU domain proteins are structurally related to the UNC-86 gene product in 
C.elegans. Brn3a, Brn3c, and Brn3b are three members of the mammalian class IV which are 
expressed in the PNS and CNS
74
 (Table 1.2.3).  
Brn5 is a member of the class VI POU domain (Table 1.2.3). Brn5 is widely expressed in 
neurons as well as tissues outside the nervous system, including, kidneys, lungs, heart, 
adrenal gland, skin, testes, and anterior pituitary
79,83
.  
1.2.3 POU transcription factors - biological roles in health and disease  
Normal development of the embryo requires a tightly regulated pattern of gene expressions, 
and deviations from this pattern are associated with phenotypical abnormalities
84
. 
Dysregulation of class III and class IV of the POU transcription factors lead to different 
deficiency (Table 1.2.3); in class III, Brn1 is essential in the development and function of the 
nephron in the kidney and it is able to regulate the androgen activity mechanism in 
kidneys
85
. Brn4 null mice have several defects in development of the inner ear causing 
deafness but there are no detectable defects in development/function of the CNS
79
. Also the 
knockout mice for class IV POU transcription factors, showed that most deficiencies 
impacted on the development of specific neuronal cell types, mainly leading to deficiency in 
ears and eyes
86
. The expression of POU domain transcription factors has been reported in 
different cancer types
69
 (Table 1.2.3). Notably, expression of Oct4 has been reported in many 
somatic cancers such as gliomas, lung cancer, breast cancer, prostate cancer, non-small cell, 
bladder cancer, oral squamous cell carcinoma, gastric cancer, and esophageal cancer
64
 (Table 
1.2.3). Expression of Brn1(class III) and Brn3b (class IV) are also founded in breast cancer
87
 
(more examples are listed in table 1.2.3). 
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1.2.4 POU3f2 – expression patterns and biological function 
POU3f2 (Brain2, Brn2,N-Oct-3, Oct7) is an intron less member of the class III POU domain 
and is located on chromosome 6q16 in humans
74,68,88,89
. POU3f2 binds the octameric 
sequence of ATG(C/T)TAAT, but the majority of POU3f2 binding sites are a consensus 
non-octameric sequence ATG(A/C)AT(A/T)0-2ATTNAT
90
. In adults, expression of POU3f2 
is restricted to the hypothalamus and part of the cortex
69
 while it is expressed widely  in the 
CNS during embryogenesis
74
. POU3f2 is a critical regulator of cell differentiation along 
neuronal and glial cell lineages
70
. Moreover, it is involved in the production and positioning 
of neocortical neurons
91,92
. In POU3f2-null mice, migratory precursor cell neurons of the 
paraventricular nuclei and supraoptic nuclei of hypothalamus die at E12.5
93
. The POU3f2 
null mice are live born, but smaller in size compared to wild type mice
79
. Furthermore, they 
show severe malnutrition and decrease in brown adipose tissue, and usually die within day 
10 after birth
74,79
. Moreover, POU3f2 is involved in the production and positioning of 
neocortical neurons
91,92
. POU3f2 is necessary for the differentiation of neurosecretory 
neurons in the posterior pituitary gland
69,76,94
. POU3f2 null mice show vast hypocellularity in 
the posterior pituitary gland. Here, POU3f2 is expressed primarily in neurons which are 
responsible for oxytocin and corticotropin releasing hormone (CRH) expression
74,95,76
. 
POU3f2 expression in combination with Asc1l, and Myt1l has been shown to convert 
fibroblast into neurons, astrocytes and oligodendrocytes
96
. 
1.2.5 POU3f2 in tumor development 
POU3f2 is aberrantly expressed in several malignancies, such as melanoma
68
, small cell lung 
carcinoma
97
, neuroblastoma, merkel cell carcinoma and glioblastoma
70
. Moreover, based on 
The Human Protein Atlas Database, POU3f2 is expressed in cancer cell lines from various 
cancer types
98
. Publications concerning POU3f2 are rare; most research has investigated 
POU3f2 on melanomas
68,69,70
, additionally nobody has yet systematically considered 
POU3f2 expression patterns in human gliomas albeit little data is available for the expression 
of POU3f2 in normal brains
99,88
 and in brain tumors
100
. 
In normal tissue, differentiation of immature melanoblasts into pigmented melanocytes is 
associated with downregulation of POU3f2, while dedifferentiation of fully mature 
melanocytes to non-pigmented melanoblasts is correlated with an increase of POU3f2
69
. 
Notably, POU3f2 expression in melanomas is much higher than in primary melanocytes
69,70
. 
Upregulation of POU3f2 and is associated with proliferation and invasion
101
 suggesting that 
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this upregulation is a critical step in melanoma progression
70
. Retinoblastoma (Rb) cells and 
small cell lung cancers are other tumors displaying POU3f2 expression. In both the Rb is 
typically mutated suggesting a link between dysregulated POU3f2 expression and 
retinoblastoma tumorgenesis
102
. 
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2. Aims 
2.1 Hypothesis 
CNS neuronal and glial cell types share a common neuroectodermal origin with 
melanocytes. Moreover, the fetal transcription POU3f2 is highly expressed during neuronal 
development and in immature melanoblasts. Thus, it is possible that tumors arising from 
these tissues also display similarities. Since several studies have shown that POU3f2 is 
expressed at high levels in melanomas, we therefore hypothesized that POU3f2 is expressed 
in human gliomas. 
 
 
 
 
2.2 Aims 
1. To investigate the expression of POU3f2 in human glioma biopsies. 
2. To investigate how POU3f2 impacts on proliferation and colony formation in 
genetically modified U251 glioma cells with overexpression and knock down for the 
POU3f2 gene. 
3. To investigate how POU3f2 impacts on tumor growth in vivo by xenografting the 
above mentioned glioma cell line in mice. 
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3. Materials  
 
 
 
 
 
 
Table 3.1: Software 
Table 3.2: Cell lines 
Table 3.3: Primary Antibodies for ICC, IHC and Western blot 
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Table 3.4: Secondary Antibodies 
 
Table 3.5: Primers for qRT-PCR 
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4. Methods 
4.1 Cell handling 
4.1.1 Cell culture 
All work areas and equipment were disinfected with 70% ethanol and all cell handling 
procedures were done under a laminar flow hood (NUAIRE, Plymouth, Minnesota, USA). 
The cells were maintained in tissue culture incubators (SANYO Electric Co.Ltd, Moriguchi 
City, Osaka, Japan) at 37 
ₒ
C with 5% CO2, 100% humidity and 95% air. Depending on the 
number of cells that were needed for experiments, three different sizes (25 cm
2
, 75cm
2 
and 
175cm
2
) of culture flask (Nunc, Thermo Fischer Scientific, Waltham, kamstrupvej90, 
Denmark) were used for cell culturing. The adherent cells were cultivated as monolayers to 
80-90% confluency in Dulbeccos Modified Eagles Medium (DMEM-ALT (DMEM 
supplemented w. 10% heat inactivated calf serum, four times the prescribed amount of non-
essential amino acids, L-Glutamine, penicillin (100 μg/ml) and streptomycin (100 μg/ml)) 
(Sigma Aldrich, St. Louis, Missouri, USA). To passage cells, the old medium was removed 
and cells were washed twice with 1X PBS (phosphate buffered saline) (Sigma Aldrich, St. 
Louis, Missouri, USA). Then, the cells were detached by incubation at 37ºC in Trypsin-
EDTA (Lonza, Basel, Switzerland) for 3-5 minutes. The effect of the trypsin was deactivated 
by adding DMEM-ALT. About 80% of the cells were discarded, and fresh DMEM-ALT was 
added. The passage number was registered each time that cells were passaged. 
4.1.2 Cryopreservation of cells 
Cells were frozen down for cryopreservation at the first passaging of newly thawed cells, for 
later use. For cryopreservation, cells were harvested when they were approximately 80% 
confluent. Trypsinization was performed as previously explained and approximately 1,8X10
7
 
cells were transferred into a 15 ml centrifuge tube (Thermo Scientific Nunc, Rochester, 
USA) and centrifuged at 900g for 5 minutes. Supernatant was discarded and pelleted cells 
were resuspended in 8 ml of freezing solution (1 ml DMSO (Sigma-Aldrich, St. Louis, 
Missouri, USA), 1 ml 10% FBS (Invitrogen, Carlsbad, California, USA) and 6 ml medium). 
The suspensions were aliquated into 8 cryotubes (1 ml each) (Nunc, Thermo Fischer 
Scientific, Waltham, Massachusetts, USA) and placed in an isopropanol container in -80ºC 
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freezer overnight. After 24 hours the cryotubes were transferred to a liquid nitrogen tank 
maintained.  
4.1.3 Thawing of cells 
Cells were thawed at 37°C in a water-bath. Thereafter, the cell suspension (1 ml) was 
transferred to a 25 mm
2
 flask containing 10 ml DMEM-ALT. The medium was replaced with 
10 ml of fresh medium after 24 hours.  
4.1.4 Counting of the cells 
Depending on the type of the experiments, cells were counted before, during or after the 
experiment, using a Burker chamber (hemocytometer or counting chamber) (Marienfeld-
Superior, Lauda-Königshofen, Germany). Burker chambers contain a big central square with 
9 squares, and each of these 9 squares encloses 16 smaller squares. The numbers of cells 
were counted in 3 of 9 squares and divided by three to achieve the average number of cells 
per square. This number was multiplied by 10
4
 to estimate the number of the cells per 
milliliter. An inverted light microscope was used for cell counting and cell monitoring. 
4.2 Cryostat tissue sectioning 
A cryostat (Leica CM 3050S Cryostat, Nussloch, Germany) was used to prepare 
cryosections to extract DNA, RNA and protein. Sectioning performed at -20 ºC. All the 
necessary equipment was placed in the cryostat chamber before using. The tissue samples 
were taken from nitrogen tank and the temperature was increased to -20ºC and then 
embedded into an optimal cutting temperature compound (O.C.T) (Sakura Finetek, Torrance, 
California, USA) and sectioned to a 10-12 µm. About 40-60 of the sections (depending on 
the size of the samples) were collected for DNA, RNA and protein extraction (the samples 
were stored at -80ºC until using). Control sections were inspected microscopically to confirm 
that they contained tumor tissue. 
4.3 Hematoxylin and Eosin (H&E) Staining 
Prepared slides from the cryostat were immersed in 50% ethanol/methanol (Sigma-Aldrich, 
St. Louis, Missouri, USA) for 5 minutes and dried at room temperature for 10 minutes. 
Thereafter, the slides were stained for 1 minute by hematoxylin (Cellpath, Newtown, Powys, 
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UK) and were washed in running tap water until the water was clear. The sections were 
stained with eosin (1gram eosin, 20 ml distilled water, 180 ml 96% ethanol) for 20 seconds 
and the excess eosin was rinsed away in several changes of tap water. Sections were 
dehydrated in 96% ethanol (2 minutes) and 100% ethanol (2 minutes), and then placed in 
Xylol (Sigma-Aldrich, St. Louis, Missouri, USA) for 4 minutes. Finally, a glass coverslip 
was mounted on Entellan (Merck, Darmstadt, Germany) on top of the sections.  
4.4 Immunohistochemistry 
4.4.1 Immunohistochemistry 
In this study the Avidin-Biotin complex (ABC) method was used on samples of formalin 
fixed paraffin embedded tissue sections. Briefly, this method uses a biotinylated secondary 
antibody and subsequent addition of an avidin-biotin complex (ABC reagent)
103
. 
4.4.2 Deparaffinising and dehydration 
The slides were dipped in Xylol twice (Sigma Aldrich, St. Louis, Missouri, USA) 5 minutes 
each time, transferred to absolute ethanol twice, and then 96% ethanol twice, 3 minutes for 
each wash. Finally, slides were immersed in Milli-Q water for 2 minutes. 
4.4.3 Antigen retrieval 
Heat induced epitope retrieval (HIER) was used for antigen retrieving
104
. The slides were 
placed in boiling citrate buffer (pH 6) and incubated in a 98°C water bath (IKA-WERKE, 
Germany) for 20 minutes. The container was cooled down at room temperature (RT) for 15 
minutes and subsequently then kept in running water for 10 minutes. The tissue sections 
were encircled with a water-repellant hydrophobic barrier pen (ImmEdge pen, Burlingame, 
California, USA). Thereafter, TBS w/Tween (0.05M Tris, pH 7.2-7.6, 0.3 M NaCl, 0.1% 
Tween 20 (Sigma Aldrich, St. Louis, Missouri, USA)) was added on each section and the 
slides were then washed by TBS w/Tween two times for 3 minutes. 
4.4.4 Blocking and antibody treatment 
TBS w/Tween was sucked up and replaced by a blocking buffer (Bovine Serum Albumin 
(BSA)) (5 mg/ml) (Sigma Aldrich, St. Louis, Missouri, USA) and incubated for 30 minutes 
at RT. Next, the primary antibody (Table 3.3) was diluted in the blocking buffer, added to 
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the sections and incubated for 1 hour at RT or incubated overnight at 4°C in a humidified 
chamber (depending on the antibody). Then slides washed by TBS w/Tween 3x3 minutes. 
hydrogen peroxide (hydrogen peroxide (30 µl/ml) was diluted in 1X PBS) and added for 5 
minutes at RT, and washed by TBS w/Tween three times for 3 minutes each. Thereafter, a 
biotin-conjugated secondary antibody (Table 3.4) was diluted in the blocking buffer and 
added to the sections for 1 hour at RT, before slides were washed as described in earlier 
steps. The Avidin-biotin complex (ABC Reagent) (Vector Laboratories Inc., Burlingame, 
California, USA) was added for 30 minutes at RT. After washing three times with TBS 
w/Tween washing buffer, 100 µl of DAB substrate-chromogen (1 drop of 3,3'-
diaminobenzidine in chromogen solution + 1ml of Imidazole-HCl buffer, pH 7.5, containing 
hydrogen peroxide and an anti-microbial agent) (Dako, Carpinteria, California, USA) was 
added to the sections for varying time durations (30 second to 7 minutes). Then the sections 
were washed by Milli-Q water first and then immersed in Milli-Q water until next step. The 
substrate reaction was monitored through a light microscope. For negative control just 
secondary antibody was added to the samples. 
4.4.5 Counterstaining and dehydration 
The slides were dipped in hematoxylin (filtered before use) for 60-90 seconds and washed in 
running tap water. The sections were dehydrated by dipping the slides in different 
percentages of ethanol and absolute xylene as follows: distilled water 2 minutes, 96% 
ethanol 2x3 minutes, absolute ethanol 2x3 minutes and xylene 2x5 minutes. 
4.4.6 Mounting 
Entellan (xylene-base mounting medium) was added on xylene-wet sections and then a 
coverslip was mounted on top. The light microscope was used for analyzing the sections.  
4.4.7 Percentage Calculation for expression of interest protein 
The POU3f2 staining was predominantly nculear which allowed us to estimate the nuclear 
labelling index as the fraction of immunopositive nuclei compared to all (immunopositive 
and negative nuclei). Each image was divided into 16 parts and 3 out of the 16 grids for each 
sample (the grid pattern was same for all the samples) were assessed at 200x magnification.  
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4.4.8 Optimization 
Five antibodies (against POU3f2) from different companies (Millipore Corporation, Cell 
Signaling Technology, Santa Cruz Biotechnology, Life Span Technologies, Protein Tech 
Group) were tested, and optimized for both dilution (1:100, 1:200, 1:500, 1:1000) and 
incubation time (1 hour or overnight).  
4.5 Immunocytochemistry 
4.5.1 Immunocytochemistry 
In this study, we used an indirect method
105
 for detecting cellular protein with a secondary 
antibody conjugated to a fluorescent tag – a fluorophore. 
4.5.2 Sample preparation 
Sterile 12 mm coverslips were placed in a 24-well plate and 20000-40000 cells were seeded 
on each coverslip. The amount of DMEM-ALT was increased to 1 ml in each well and the 
cells were maintained in tissue culture incubators at 37ºC with 5% CO2, 100% humidity and 
95% air. At 70-80% confluency, the cells were washed 2 times with 1X PBS after removing 
the old media. To fix the cells, about 500 µl of paraformaldehyde (40 mg/ml, diluted in 1X 
PBS) (Thermo scientific, Rockford, Illinois, USA) was added to each well and incubated for 
10 minutes at room temperature. Next, the paraformaldehyde was removed and 500 µl of 
Triton X-100 (5 µl/ml, diluted in 1x PBS) (Sigma Aldrich, St. Louis, Missouri, USA)) was 
added to each well for 4 minutes to permeabilize the cells. After removing the Triton X-100, 
the cells were washed with 1X PBS 3 times and stored in 1X PBS at 4 ºC.  
4.5.3 Immunostaining 
A humidified box covered with parafilm used for the procedure. The cells were blocked by 
bovine serum albumin (BSA) (5mg/ml, diluted in 1x PBS) (Sigma Aldrich, St. Louis, 
Missouri, USA) for 15 minutes at RT. Subsequently, cells were incubated with the primary 
antibody (diluted in BSA (5mg/ml) in 1x PBS) (Table 3.3) overnight at 4 ºC. Then, cells 
were washed for 3x3 minutes with 1X PBS and then incubated with the secondary antibody 
(diluted in BSA (5mg/ml) in 1X PBS) (Table 3.4) for 45 minutes at 37     fterwards, cells 
were washed with 1X PBS for 3x3 minutes. Subsequent steps were conducted with the lights 
off. 5 μl Prolong Gold (mounting solution) antifade reagent containing 4',6-diamidino-2-
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phenylindole (DAPI) (Invitrogen, Eugene, Oregon, USA) was added to the glass slides, 
before the coverslips were mounted on the sections. The mounting solution was allowed to 
dry overnight. For negative control, the primary antibody was omitted from the procedure. 
4.5.4 Fluorescence imaging 
The Nikon TE2000 inverted microscope (Nikon instrument, Inc. Tokyo, Japan) was used to 
examine the ICC samples. This microscope is equipped with a mercury arc lamp, and a set of 
fluorescence filters ranging from UV to far red. Bandpass filters were used to capture the 
different required wavelengths. 
4.6 Protein immunoblotting 
4.6.1 Immunoblotting 
Immunoblotting (Western blotting (WB)) is used to detect a protein of interest in a protein 
mixture. In immunoblotting the proteins are generally sorted by molecular weight and the 
separated protein bands are then transferred to a membrane. The membrane is incubated with 
primary and secondary antibodies for the stipulated duration of time. Subsequently, 
antibodies bind to the interest protein and make the protein band visible
106
.  
4.6.2 Protein isolation 
Proteins were extracted from cells or brain tumor tissue. To extract proteins from the cells, 
they were seeded in a 25 mm
2
 flask and incubated at 37°C with 5% CO2, until the 
cells reached 80-90% confluency. Then, media was removed and the cells were washed with 
cold 1X PBS twice. While the flask was placed on ice, 200 μl Kinexus protein lysis buffer 
(500 mM MOPS, 500 mM EDTA, 100 mM EGTA, 500 mM NaF, 10% Triton X, 100 mM 
PMSF ((in isopropanol), pH 7.2), protease inhibitor cocktail tablet (Roche, Mannheim, 
Germany) and phosphatase inhibitors cocktail tablets (Roche, Mannheim, Germany) (each 
10 ml of Kinesus protein lysis buffer contained 1 tablet of protease and phosphatase 
inhibitor) were added to the cells and after 5 minutes incubation on ice, the cells were 
collected by cell scrapers and transferred to a 1,5 eppendorf tube and incubated on ice again 
for 5 minutes. For more disruption of the cell membranes, a sonicator (Sonics Vibra-Cell, 
Illinois, USA) was used at 20 Hz for 3x2 seconds. Samples were centrifuged at 13200 for 30 
minutes at 4 ºC. The supernatant was transferred to a new 1.5 ml eppendorf tube and stored 
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at -20 
º
C. To extract the brain tumor tissue, 200 μl Kinexus protein lysis buffer was added to 
the tissue sections, which had been homogenized using a small pestle (the pestle was 
changed sample by sample). After homogenization, tissue samples were sonicated and 
centrifuged; the supernatant was stored in the same way the cell lines. 
4.6.3 Measurement of protein concentration 
The protein concentration was measured using NanoDrop 1000 Spectrophotometer (Thermo 
Fisher Scientific). Based on the nanodrop manual 2 µl of Kinexus protein lysis buffer was 
added to the lower measurement pedestal of nanodrop as a blank and then 2 µl of each 
protein sample was loaded for measurement
107
. After each measurement, the lower and upper 
pedestals were wiped by a soft laboratory wiper and then the next sample was loaded for 
concentration measurement. Nanodrop is able to detect absorbance wavelengths between 
220-750 nm and it measures the protein absorbance at 280 nm and calculates the 
concentration in mg/ml. 
4.6.4 Sample preparation and SDS-PAGE 
To prepare the sample for SDS-PAGE gel electrophoresis, 10-40 µg of protein was mixed 
with 2.5 µl of reducing agent (Invitrogen, Carlsbad, California, USA), 7.5 µl of 4X LDS 
sample buffer (Invitrogen) and distilled water (dH2O) was added until the total volume 
reached 30 µl. The samples were boiled for 10 minutes at 70°C and then briefly centrifuged 
(10000 g for 30 seconds). A 10-well NuPage (1.5 mm) 4-12% Bis-Tris gel (Invitrogen) was 
assembled using a Novex mini-cell gel chamber (Invitrogen), the inner chamber was filled 
with 200 ml 1X NuPage MES Running Buffer (Invitrogen) including 500 μl of antioxidant 
(Invitrogen) and the outer chamber was filled with 600 ml of 1X running buffer. To remove 
any air bubbles, wells of the gel were flushed with running buffer before loading. 
Subsequently, 5 µl of SeeBlue plus 2 Prestained Standard (Invitrogen) were loaded to the gel 
as molecular weight standard and 30 µl of each sample mixture was loaded next to the 
molecular weight standard. The mini-cell gel chamber was placed onto ice and the 
electrophoresis was run at 140 V for 85 min.  
4.6.5 Blotting  
Separation of proteins on the SDS-PAGE is required before transfer onto a nitrocellulose 
membrane (blotting). Electrical current was used to transfer protein from the SDS-PAGE to 
the nitrocellulose membrane. Three blotting pads, one filter paper, the SDS-Gel, 0.2 µm 
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nitrocellulose membrane (Whatman International Ltd., Kent, UK), one filterpaper and three 
blotting pads again were assembled in an XCell II Blot Module from cathode to anode 
respectively and fixed in a Novex mini-cell gel chamber. The transfer chamber was filled 
with transfer buffer (25 ml 20X transfer buffer (Invitrogen), 50 ml methanol and 500 µl 
antioxidant (Invitrogen) were filled up to 500 ml with MilliQ-water) and the outer chamber 
was filled with MilliQ-water. Finally, the Novex mini-cell gel chamber was placed on the ice 
and transferring was run at 30 V for 80 minutes. Before assembling, all the components 
except the gel were soaked in the prepared transfer buffer; moreover, a roller was used to 
expel air bubbles between the layers. 
4.6.6 Ponceau S staining 
After blotting, the nitrocellulose membrane was washed in MilliQ-water and was then 
incubated in Ponceau S dye (0.1% ponceau S dye in 5% acetic acid) for 10 minutes at room 
temperature to verify the efficiency of the transferring. Thereafter, the membrane was 
washed with MilliQ-water to remove any excess dye. For further analysis, the membrane 
was scanned after staining. Finally, the membrane was cut based on the molecular weight of 
the target protein and used for blocking and for subsequent steps. 
4.6.7 Blocking and antibody incubation 
In order to block unspecific binding, a nitrocellulose membrane was incubated in blocking 
buffer (Difco Skim Milk Powder (50 mg/ml)) diluted in 1X TBS w/Tween) (BD 
Biosciences, Franklin, Lakes, New Jersey, USA) for 1 hour at RT while gently shaking. The 
primary and secondary antibodies were diluted in blocking buffer (Table 3.3 and table 3.4). 
Thereafter, the membrane was incubated with the primary antibody at 4°C overnight. Next, 
the membrane was washed with TBS w/Tween (20 ml 0.5 M Tris/HCl pH 7.5, 75 ml 1M 
NaCl, 0.5 ml Tween 20, Adjusted to 500 ml with MilliQ H2O) for 4x10 minutes at RT. After 
that, the membrane was incubated with the secondary antibody (Table 3.4) for 90 minutes at 
RT and was then washed using TBS w/Tween for 4x10 minutes. The incubation and washing 
step were done on the shaking board. The housekeeping gene GAPDH (Glyceraldehyde-3-
phosphate-dehydrogenase) was used as an internal control to check the quantity of the loaded 
protein for each patient (Table 3.3). 
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4.6.8 Chemiluminescence and quantification of protein expression 
In order to visualize the protein-antibody interaction, a membrane was incubated with Super 
Signal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) for 5 minutes at RT. Super Signal West Femto Substrate with 
horseradish peroxidase (HRP) enzyme used for immunoblotting. The luminescent image 
analyzer LAS-3000 (Fujifilm Medical Systems Inc., Stamford, Connecticut, USA) was used 
for imaging. Finally, the relative proteins expression levels were quantified using Image J 
software (NIH, Maryland, USA) based on the software’s guidelines108. In this procedure, the 
band density of each protein was normalized with the band density of the GAPDH for the 
same patient. Subsequently, the relative density was calculated for all the samples. 
4.6.9 Optimization 
To determine the optimal protein concentration the western blot experiment, different 
concentrations (10-50 µg) of the protein mixtures (human gliomas samples) were loaded on 
the gel. Based on this procedure we decided to load 40 µg of protein from each sample. 
4.7 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
4.7.1 qRT-PCR 
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) is a technique used to 
amplify and quantify a DNA sequence of interst
109
. qRT-PCR is based on the polymerase 
chain reaction (PCR) in which a quantity of the interest sequence is detected by fluorescent 
dye; the fluorescent dye can intercalate to the double strand DNA non-specifically or it can 
bind to the specific sequence of the DNA
109
. In this study, Non-specific DNA binding dye 
was used as a fluorescent reporter to determine the amount of the gene expression.  
4.7.2 RNA isolation 
RNA was isolated from cells and tissue samples using Qiagen RNeasy Mini kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions110. 20-30 mg of tissue was 
collected by a cryostat (according to section 4.2). To isolate RNA from the cells, cells were 
treated by trypsin-EDTA as explained in Section 4.1.1. The trypsin was inactivated by 
adding 5 ml DMEM-ALT. Next, the cells were centrifuged for 5 minutes at 900 g after 
transferring to a 15 ml tube. The cell pellet was resuspended in 1X PBS and centrifuged at 
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900 g for 5 minutes. The supernatant was removed and the pellet was collected for RNA 
extraction.  ccording to the manufacture’s instruction up to ~107 cells were used. 
4.7.3 Removal of DNA from RNA  
The RNase-Free DNase Set (Qiagen, Hilden, Germany) was used to remove residual DNA 
contamination from the RNA samples. 10 µl of DNase I stock solution was added to 70 µl of 
Buffer RDD for each RNA sample and mixed gently. Next, 80 µl of mixed solution was 
added to the RNease spin column membrane while RNA was bound to the RNeasy 
membrane and incubated for 15 minutes at RT.  
4.7.4 Measurement of RNA concentration and quality determination 
Agarose gel electrophoresis is a technique used to separate nucleic acids by size. The nucleic 
acids can migrate in the agarose gel due to the negative charge of the phosphate in the back 
bone of the nucleic acids
111
. The agarose gel electrophoresis was performed to evaluate the 
quality of the extracted RNA. 3 µl of RNA was mixed with 3 µl of 2x RNA loading dye 
(Thermo Fisher Scientific, Waltham, Massachusetts, USA) and 5 µl of the mixture was 
loaded on to 1% agarose gel (10 mg/ml in 1X Tris-Acetate-EDTA (TAE) buffer (40 mM 
Tris base, 2 mM EDTA, Acetic acid 20 mM, Adjust to pH 8.5 and dilute to 1X with Milli-Q 
H2O before use)) containing 3 µl of ethidium bromide (10 mg/ml) (Sigma Aldrich, St. Louis, 
Missouri, USA). The gel run for 30 minutes at 100 V. Finally, a UV-imager (Fujifilm 
Medical Systems Inc., Stamford, Connecticut, USA) was used to scan the gel. The RNA 
concentration was measured by a NanoDrop1000 Spectrophotometer (Thermo Fisher 
Scientific). Based on manual instruction, 1 µl of RNA was loaded to the lower measurement 
pedestal and Nuclease free water was used as a blank. The Nanodrop measures the Nucleic 
acid absorbance at 260 nm and calculates the concentration in ng/µl
107
. 
4.7.5 cDNA synthesis and determination of cDNA concentration 
Making complementary DNA (cDNA) from RNA is a necessary process for performing 
quantitative qRT-PCR. The iScriptc DNA Synthesis kit (BIO-RAD, Hercules, California, 
USA) was used for making cDNA from RNA. To make cDNA, according to the 
manufacturer’s instructions 4 µl of 5X  iscript mix, 1 µl of iscript reverse transcriptase, x µl 
of Nuclease-free water and x µl of RNA template (250 ng RNA was used for each sample) 
were mixed to a total volume of 20 µl. The mixture was incubated for 5 minutes at 25°C, 30 
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minutes at 42°C and 5 minutes at 85°C by using a Peltier Thermal Cycle (BIO-RAD, 
Massachusetts, USA). Finally, the cDNA was diluted 10 times and stored at -20ºC. 
4.7.6 Plate preparation, running and analysis 
The iQ SYBR Green Supermix kit (BIO-RAD, USA) was used to perform qRT-PCR. For 
one reaction, 5 μl of iQ SYBR Green Supermix, 2 μl of 1 μM primer pairs (Table 3.5), 1 μl 
of Nuclease-free water and 2 μl of cDNA were loaded on a 384 well plate. Each sample was 
loaded in triplicates and each plate was run three times on a Roche LC480 instrument (Roche 
Applied Science, Germany). The resultant qRT-PCR program was used to perform thermal 
cycles: Initial denaturation 95 
◦
C – 5 min, denaturation 95 ◦C – 10 sec, annealing 60 ◦C - 10 
sec, extension 72 
◦
C – 10 sec, final extension 72 ◦C - 5 min and finally, held in 4 ◦C. Non-
Template Control (primer was added to master mix without any cDNA) was run to check the 
possibility of dimer formation and non-specific amplification. In all qRT-PCR experiment, 
the eukaryotic ribosomal gene 18S was used as a control (Table 3.5).  
Finally, the ΔΔ T method was used to calculate fold change of the gene expression109.  
4.8 Lentiviral Transduction 
4.8.1 Transformation 
The lentiviral constructs (pLenti-POU3f2-GFP (Hereafter called “POU3f2 ox”) and pLenti-
GFP (Hereafter called “blank vector”), pLenti-POU3f2-siRNA-GFP (Hereafter called 
“POU3f2 siRN ”) and pLenti-Scrambled siRNA-GFP (Hereafter called “scrambled 
siRN ”)) were bought commercially from Applied Biological Materials, Canada. To 
amplify these plasmids, a heat shock method was used to transform the plasmid of interest to 
the bacteria
112
. The NEB10-beta competent Escherichia coli (E. coli) (New England Biolabs, 
MA, USA) were thawed on ice and 10 ng of plasmid DNA was added to 30 µl of the cells. 
The cells and plasmid were mixed by gentle flicking in the microcentrifuge tube. The tube 
was incubated on ice for 20 minutes and heat shock was performed by placing the 
microcentrifuge tube into a 42
º
C water bath for 45 seconds. Thereafter, the tube was placed 
on ice for 5 minutes. After 5 minutes of incubation on ice, 450 µl of prewarmed Super 
Optimal broth with Catabolite repression medium (SOC medium) was added to the mixture 
and incubated for 1 hour at 37ºC in a shaking incubator at 200 rpm. Subsequently, 100 µl of 
transformed bacteria was added to Lysogeny broth agar (LB agar plate) (Tryptone (1 
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mg/ml), yeast extract (0.5 mg/ml), Nacl (1 mg/ml) in 1 liter H2O, pH adjusted to 7.0 with 5 
N NaOH, 15 mg/ml agar dissolved in 1 liter of LB medium) containing 50 µg/µl kanamycin 
and the bacteria suspension was spread using a sterile glass spreader. The plates were left 
about 10 minutes before incubation at 37 
◦
C overnight. 
4.8.2 Plasmid purification 
One of the transformed bacterial colonies was taken and added to 20 ml of LB medium 
containing kanamycin (50µg/ml) and incubated overnight at 37°C while shaking at 200 rpm. 
Next day, 19 ml of the bacteria were transferred to a new tube and the tube was centrifuged 
for 30 minutes at 4000 rpm. Supernatant was removed and the pellet was used for plasmid 
purification. E.Z.N.A.® Plasmid DNA Mini Kit II (Omega bio-tek, Georgia, USA) was used 
to purify plasmid DNA according to the manufacturer’s instructions. 
4.8.3 Restriction digestion 
Plasmids were digested by a restriction enzyme and agarose gel electrophoresis was 
performed to confirm the identity of the plasmids. Digestion of the plasmids was performed 
by preparation of a 10 µl mixture including 1 µl DNA, 0.5 µl Enzyme (PstI (pLenti-POU3f2-
GFP and pLenti-GFP), SmaI (pLenti-POU3f2 siRNA-GFP and pLenti-Scrambled siRNA-
GFP)) (Promega, Wisconsin, USA), 1 µl 10X buffer, 0.1 µl BSA and 7.4 µl of water. The 
mixture was incubated at optimum temperature of the enzyme (SmaI: 25ºC and PstI: 37ºC) 
for two hours. Thereafter, samples were electrophoresed through 1% agarose gel (10 mg/ml 
in 1X TAE buffer) containing 3 µl of ethidium bromide. 6 µl of DNA was mixed with 1µl of 
loading dye (6X) (Thermo Scientific Nunc, Rochester, USA), and 5µl of 1KB DNA marker 
standard (Thermo Scientific) was loaded to the first well. The gel run at 100V for 25 
minutes. 
4.8.4 Lentivirus production: CaPO
4
 transfection 
For virus production, 1.6×10
6
 293T cells were seeded in a small flask and incubated at 37ºC 
with 5% CO2 overnight until the cells reached 70-80% confluency. The next day, the 
medium was replaced with an 8ml low Pen/Strep medium containing DMEM (42.9 ml), 
pen/strep (100 µl), glutamine (1 ml), non-essential amino acid (1 ml) and FBS (5 ml). Next, 
528 µl of BES-buffered saline 2X (BBS) was added in drops to the mixture of plasmids 
including 106 µl of Cacl2 (2M), GagPol Rev (M334) (1130 ng), Env (M5) (268 ng), 
lentiviral vector (4178 ng) and 422 µl of dH2O and mixed well by pipetting up and down. 
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After 15 minutes of incubation at RT, 1054 µl of the mixture was added drop by drop to 
flasks containing 293T cells and incubated at 37ºC with 3% CO2. The next day, transfection 
efficiency was evaluated by fluorescent microscopy in order to check the presence of GFP in 
lentiviral plasmids. Thereafter, the medium was replaced with fresh DMEM-ALT and the 
virus was collected during at the next two days. Viruses were filtered by a 0.2 µm filter 
(Acrodisc Syringe Filter, Pall Life Sciences, USA) and stored at -80°C.  
4.8.5 Lentiviral infection 
For cell infection, 4×10
4
 cells were seeded in a 24 well plate, and cells were incubated 
overnight at 37ºC with 5% CO2. The next day, a different dilution of viruses (100, 200, 300 
µl) with 1µl of polybrene (5mg/ml) was added to each well (different wells with the same 
cell lines). Plates were centrifuged at 2250 rpm for 90 min at 3ºC and then incubated at 37ºC 
with 5% CO2. After successful transfection, positive cells were selected with puromycin, and 
were sorted by FACS (fluorescence activated cell sorting). This step was performed by a 
collaborator. The positive cells were cultured and used for planned experiments. 
4.9 Proliferation assay 
Growth curves were established to characterize cell proliferation for different cell lines. 
15000 cells were seeded in each of three small flasks and the flasks were kept at 37ºC with 
5% CO2. The number of cells in each flask was counted every third day until day 12 (day 3, 
6, 9 and 12). To count the cells, they were trypsinized (Section 4.1.1) and 10 µl of cell 
suspension was loaded into a Burker chamber (Section 4.1.4). The average number of the 
cells in the three flasks was used to determine the growth curve. The proliferation assay was 
performed two times. 
4.10 Clonogenic assay 
To perform clonogenic assay, 500 cells were seeded into a six-well plate and then the plates 
were incubated in a normoxic incubator for 10 days. At day 10, the medium was removed, 
and wells were washed with 1X PBS. Thereafter, to fix the cells, 500 µl of paraformaldehyde 
(40 mg/ml, diluted in 1X PBS) was added to each well and left for 5 minutes. After fixation, 
the paraformaldehyde was removed, and crystal violet solution was added to the wells for 15 
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minutes. Finally, the wells were washed with tap water and the plates were dried with air. 
The clonogenic assay was repeated there times. 
4.11 Animal experiment 
An in vivo animal experiment was performed to investigate the function of the POU3f2. In 
this experiment, U251MG (Hereafter called U251) cell lines (U251 POU3f2 ox, U251 
POU3f2 siRNA and U251 scrambled siRNA) were implanted in intracerebrally in NOD-
SCID mice. The mice were kept on a standard pellet diet, in a pathogen free environment at a 
constant temperature and humidity, on a standard 12/12 h light and dark cycle. The animals 
were provided a standard pellet diet and tap water ad libitum. Tumor formation was checked 
by a Positron emission tomography (PET) scan. This procedure involves the use of 
radioactive tracers and is therefore organised as a service platform, with specially trained 
personnel performing the experiments. 
4.11.1 Animal welfare 
Animal experiments were done in accordance with the Norwegian Animal Welfare 
regulations and all experimental procedures were approved by the Norwegian Animal 
Research Authority (Oslo, Norway).   
4.11.2 Animal preparation and cell implantation 
For anesthesia, the mice were kept in a chamber containing 5% isofluran until they became 
unconscious. The unconscious animals were then placed in Stereotactic frame (KOPF, 
Tujunga, California, USA) (Fig 4.11.2 A and Fig 4.11.2 B) while 2.5% isofluran was 
administered through a mask covering the nose and mouth of the mice. Before the operation, 
0.5 ml Marcain (AstraZeneca, North Ryde NSW, Australia) was injected subcutaneously in 
the location of the surgery, and an incision was made on the scalp, (Fig 4.11.2 B). Then we 
found the point where Coronal Suture and Sagittal Suture meet, thereafter, from this point, 
we located 1.0 mm posterior to the coronal suture and 1.5 mm right of the midline (Fig 
4.11.2 C). We drilled a hole in the marked location and entered the needle 2.5 mm below the 
cortical surface. 7.5×10
5
 cells from each cell line (U251 POU3f2 ox, U251 POU3f2 siRNA 
and U251 scrambled siRNA) were injected into the mouse brain gradually (Fig 4.11.2 D). 
The skin was closed with 3 stitches. The mice were kept in an infant incubator until they 
became conscious; they were then transferred to the standard cage. 
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Figure 4.11.2 A. Stereotactic frame. B. A fixed mouse is shown in this figure. The mouse is held in position 
with nose and ear bars while 5% isofluran is streamed over mouse face. C. The approximate location of the 
injection is shown by X letter. D. 750000 cells were injected 2 cm deep into the mouse brain and the skin was 
closed by 3 stiches.  
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4.12 Statistical Analysis 
Statistical analyses were conducted with the Graphpad Prism software version, 6.04 (Trial 
version). For the labeling indices on IHC, western blot and qPCR quantifications, gaussian 
distribution was assessed using the Shapiro-Wilk normality test. Neither band densities from 
western blots, labeling indices on IHC nor the qPCR values passed the normality test and we 
therefore used the non-parametric Kruskal-Walis to analyse the datasets from the three 
groups, followed by comparing the individual groups using Dunn’s multiple comparison test  
The results are presented as the average values± standard error of mean. Growth curves in 
the proliferation assay were compared using the Two-way ANOVA with repeated measures, 
followed by correction for multiple testing. Survival data were entered using the Kaplan-
Meier survival plot, and the curves were compared using the logrank test. A p-value of ≤0 05 
was considered significant. 
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5. Result 
In this study, expression of POU3f2 was examined in a panel of approximately 40-50 human 
glioma biopsies (IHC=51 samples, WB= 37 samples and qRT-PCR=38 samples), and 
subsequently performed functional studies to establish how POU3f2 expression impacted on 
glioma cell growth in vitro and in vivo. 
5.1 Investigation of POU3f2 expression in glioma patients by 
immunohistochemistry 
In order to investigate the spatial distribution of POU3f2 expression in brain tumors, and its 
possible correlation with the malignancy grade, IHC was performed with 51 formalin fixed 
paraffin embedded patient biopsies from grade II-IV gliomas.  
5.1.1 Evaluation of antibody specificity for POU3f2 
In order to identify reliable antibodies against human POU3f2 for subsequent work, we 
obtained and validated five antibodies (against POU3f2) from different commercial 
providers (Section 4.4.8). Two samples series from two different GBM patients were stained 
with all 5 antibodies (anti-POU3f2) separately using their optimal dilution and incubation 
time (Fig 5.1.1). We found that all five antibodies gave a positive staining in paraffin 
sections against POU3f2. However, two of these antibodies (Life Span and Santa Cruz) 
stained almost complete sections with varying levels of intensity, suggesting unspecific 
binding (Fig 5.1.1). To assess POU3f2 expression in IHC sections, antibody from Millipore 
was selected for IHC experiment. 
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Figure 5.1.1 Antibody determination. Two randomly selected GBM patient samples were stained with 
5 different antibodies (anti-POU3f2). The Avidin-Biotin immunohistochemistry method was used 
(Section 4.4) to stain formalin fixed paraffin embedded patient biopsies and then colorless substrate, 
DAB, was added. The Avidin-biotin enzyme complex converted the DAB substrate to a brown product. 
The brown color is shown to be POU3f2-positive cells. Moreover, counterstaining was done (Section 
4.4.5) and resulted in the blue color of the POU3f2-negative cells. The magnification of the pictures is 
20x and the scale bar = 100µm. 
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5.1.2 Evaluation of POU3f2 expression in glioma patients by 
Immunohistochemistry 
Next, we conducted IHC with our validated antibody from Millipore to investigate the 
expression of POU3f2 in a larger panel of 51 biopsies from human gliomas (Fig. 5.1.2.b and 
appendix 9.1) of different grades: 11 grade II gliomas, 10 grade III gliomas and 30 grade IV 
gliomas (GBM). An expression of POU3f2 was detected in all samples of different grades 
(II, III, IV) while the rate of POU3f2 expression was highest in GBM and lowest in grade II. 
Expression of POU3f2 was predominantly observed in the nucleus of POU3f2-positive cells 
but also cytoplasmic expression was observed in some cells (FIG 5.1.2.a A), moreover, 
vessels also were stained by POU3f2 antibodies slightly (FIG 5.1.2.a B). Based on the 
nuclear POU3f2 expression, the POU3f2 nuclear labeling index (LI) was quantitated by two 
independent observers, through the visual inspection of randomly selected areas from all the 
tumor sections. The percentage of POU3f2 expression was 55.9% (+/- 4.2 SE) in grade II, 
61.8% (+/- 5.1 SE) in grade III, 86.5% (+/- 1.9 SE) in grade IV. The representative average 
of POU3f2 expression in paraffin sections is shown in figure 5.1.2.b B. POU3f2 LI was 
significantly different between the groups (P-value = 0.0001, Kruskal-Wallis). Notably, the 
POU3f2 LI in grade IV gliomas was significantly higher than in grade II (P-value  0.0001), 
and grade III (0.001˃p˃0.0001) gliomas. However, the POU3f2 LI for grade II and III 
gliomas was not significantly different. 
Figure 5.1.2.a POU3f2 staining of human glioma.  A. Cytoplasmic expression of POU3f2. B. Staining of 
vessel by POU3f2 antibody. Magnification is 20x and scale bar = 50µm 
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Figure 5.1.2.b  POU3f2 staining and average of labeling index. A. IHC staining of POU3f2 in grade II-
IV astrocytoma and grade II and III oligodendroglioma. All the images are shown with 40x magnification 
and scale bar = 50µm. B. Average of labeling index for the three grades of glioma (51 patients). Error bars 
:SEM 
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5.2 Immunobloting result for expression pattern of POU3f2 in gliomas 
patients  
In order to validate POU3f2 expression on protein levels through an alternative method I 
performed western blotting for POU3f2 expression in 37 human glioma biopsies (12 grade II 
gliomas, 12 grade III gliomas and 13 grade IV gliomas) (Fig. 5.2 A). The POU3f2 protein 
was expressed in all of the samples and displayed a band at 55 kDa in all grades. The 
average relative signal intensity for POU3f2 compared to GAPDH was calculated for each 
Figure 5.2 Immunoblotting analysis of POU3f2 in a panel of 37 gliomas patients. A. The POU3f2 
bands were detected in all patients at 55 kDa, and GAPDH bands were detected at approximately 40 
kDa. B. Average of relative signal intensity of western blotting for grades II, III and IV of glioma. Error 
bars: SEM 
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grade separately (Fig. 5.2 A). The signal intensities were 1.31 (+/- 0.26 SE) for grade II, 2.34 
(+/-0.33 SE) for grade III and 3.63 (+/-0.50 SE) for grade IV gliomas. Thus, POU3f2 
expression as measured by western blotting, increased with tumor grade, displaying 
significant differences between each tumor grade (Fig. 5.2 B). Protein expression levels on 
Western blot was significantly different between the groups (P-value = 0.0009, Kruskal-
Wallis). Upon multiple testing, we found that the POU3f2 was significantly higher in grade 
IV than grade II gliomas (0 001˃ P ˃ 0 0001)  
5.3 Expression of POU3f2 investigated by qRT-PCR 
5.3.1 RNA quality 
RNA was extracted from 38 patient samples to analyze POU3f2 RNA expression and the 
RNA quality (Section 4.7.4) was assessed by gel electrophoresis. The following criteria had 
to be fulfilled: 1) The bands representing, ribosomal subunits (18S and 28S) should be clear 
and 2) The intensity of 28S band should be approximately double that of 18S
113
 (Fig 5.3.1). 
Of these, 10 samples showed no detectable band or had poorly defined bands suggesting 
RNA degradation; for these samples, new tissue was collected again and RNA extraction 
was repeated until a good quality of RNA was obtained.  
Figure 5.3.1 Gel electrophoresis of RNA samples extracted from human glioma samples. The 
samples 3, 4, 5, 6 were regarded to have RNA of good quality, whereas the samples in lane 1 and 2 
were not. 
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5.3.2 Detection of POU3f2 and quantification of POU3f2 expression levels by qRT-
PCR 
The rate of POU3f2 expression was determined in different grades of gliomas (grade II, III, 
IV) by qRT-PCR, and the fold changes were calculated (all the samples were compared with 
one of the grade II patients, patient number 6). Moreover, POU3f2 RNA expression levels 
were correlated with tumor grades and subsequently compared with expression levels of 
POU3f2 as determined by immunoblotting and IHC. 
Melt curves illustrated the same point in all the samples suggesting amplification of a 
specific target during the qRT-PCR experiment. Some representative quantifications and 
melt curves are illustrated in figure 5.3.2.a B. 
Figure 5.3.2.a Representative quantifications and melt curves of qRT-PCR: A. 18S and POU3f2 Ct 
values in glioma patients: The X-axis shows the number of cycles, and relative fluorescence units (RFU) are 
shown on the y-axis. B: Melt curves for 18S and POU3f2 fragment: Melt curves show a single peak for each 
product indicating amplification of a specific product during qRT-PCR. The X-axis displays temperature 
(ºC) and the y-axis displays –d(RFU)/dT (d=derived). 
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Notably, the qRT-PCR experiments confirmed the IHC and western blotting experiments, 
showing that POU3f2 was widely expressed in gliomas (Fig 5.3.2.a A, 5.3.2.b A). Moreover, 
we again found that POU3f2 expression correlated with tumor grading (Fig 5.3.2.b B). The 
POU3f2 expression on qPCR also differed significantly between the groups (P-value = 0.02, 
Kruskal-Wallis)). Notably Grade IV tumors displayed a significantly higher POU3f2 
expression (average normalized expression 2.23 (+/- 0.84 SE)) than grade III gliomas 
(Average normalized expression 1.12 (+/- 0.51 SE), P = 0.03). Although expression of 
POU3f2 between grade II (average normalized expression 1.34 (+/-0.39 SE)) was lower than 
in grade III and IV gliomas these differences were not significant. 
Figure 5.3.2.b Relative expression of POU3f2 in human glioma patients. A. Relative expression of 
POU3f2 in each patient: numbers 1-12 are grade II, numbers 13-24 are grade III and numbers 25-38 
are grade IV. B. The average relative expression of POU3f2 in gliomas patients: The average relative 
expression of POU3f2 with standard error of the mean is displayed. Expression of POU3f2 was 
normalized by the housekeeping gene 18S.  
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5.4 Functional role of the POU3f2 
The almost uniform expression of POU3f2 in gliomas that increased with tumor grade, 
suggested that POU3f2 may have a role in brain tumor progression. Thus, we performed a 
series of experiments to investigate how POU3f2 impacted on various aspects of glioma cell 
behavior. 
5.4.1 Establishment of U251 glioma cell lines with constitutive overexpression or 
silencing of POU3f2 
First, we used lentiviral vectors with plasmids encoding POU3f2, blank vector, POU3f2 
siRNA and scrambled siRNA to obtain U251 glioma cell lines with overexpression or 
downregulation of POU3f2 as well as U251 expressing blank vector and scrambled siRNA. 
U251 is a commonly used glioma cell line, displaying low constitutive POU3f2 expression 
(Fig 5.4.1.e). U251 wild type cells were infected by different plasmids according to the 
protocol explained in section 4.8. All the plasmids also contained GFP (green fluorescent 
protein) and the puromycin phosphotransferase gene mediating puromycin resistance. The 
cells that contained these two genes had resistance against puromycin (via puromycin 
A 
 
 
 
 
B 
Figure 5.4.1.a Map of plasmids in POU3f2 overexpressor and POU3f2 siRNA construct. A: Plenti- 
POU3f2-GIII-CMV-GFP-2A-Puro is a POU3f2 overexpressor plasmid. Moreover, pLenti-CMV-GFP-2A-
Puro-Blank was used as a control for the POU3f2 overexpressor. The structure of the blank-plasmid was 
same as the overexpressor plasmid, but it did not contain gene sequence. B. piLenti-POU3f2-siRNA-GFP is 
a siRNA plasmid. All the plasmid contained a GFP-2A-puro sequence. Subsequently, they were resistant to 
the puromycin and were able to express Green fluoresces protein as a marker.  
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phosphotransferase) and were fluoresce green (via GFP). Therefore, transfected cell lines 
were obtained by adding puromycin. The GFP makes it possible to distinguish between cells 
with/without vectors because surviving cells (after antibiotic treatment) are also positive for 
GFP.  
The gene arrangements in plasmids are shown in figure 5.4.1.a, these plasmids were used for 
establishing different cell lines. 
Interest plasmids were transformed in E.coli and after amplification, the plasmids were 
extracted from bacteria colonies. Digested plasmid DNA was run on 1% agarose gel (section 
4.8.3) and result of the gel electrophoresis showed that the plasmids contained a DNA 
fragment of interest confirming that cloning was successful in all samples (FIG 5.4.1.b) 
Next, these plasmids were used for making a lentiviral virus (section 4.8.4) using the HEK 
293T cell line. We then infected the U251 glioma cell line with lentiviral virus containing 
POU3f2, POU3f2 siRNA, blank vector and scrambled siRNA. The cell lines were treated 
with puromycin (1-10 µg/ml), and then the positive cells were sorted and collected by using 
FACS (fluorescence activated cell sorting). Stable transfectants of the U251 glioma cell line 
expressing the various transgenes are shown in figure 5.4.1.c.  
Figure 5.4.1.b. Control digestion of constructs.  Plasmids from transformed bacteria were extracted 
and digested by a restriction enzyme (PstI (for pLenti-POU3f2-GFP and pLenti-GFP), SmaI (for pLenti-
POU3f2 siRNA-GFP)). The digested DNA was run on a 1% agarose gel. The correct bands were 
observed on the gel for all the plasmids. 
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To determine the percentage of overexpression and knock down, qRT-PCR and 
immunoblotting were performed; results demonstrated that POU3f2 was upregulated more 
than 6 fold in the POU3f2 overexpressing clone (U251 POU3f2 ox),  whereas  POU3f2 
expression was reduced approximately 80% in the U251 POU3f2 knock down cell line 
(U251 POU3f2 siRNA) (5.4.1.d).  
Knock down and over expression was also confirmed with ICC. The representative data is 
shown in figure 5.4.1.e. ICC results showed that all the cell lines (U251 wild type, U251 
POU3f2 ox and U251 POU3f2 siRNA) are expressing POU3f2, but the amount of 
expression in the over expresser is higher than wild type while the knockdown cell line 
showed a lesser expression of POU3f2 in comparison with the wild type (Fig 5.4.1.e). The 
ICC results illustrated that POU3f2 is expressed in the nucleus (Fig 5.4.1.e). This data 
showed that the transfection of the cells was completely successful. These stable cell lines 
were used for following functional assay. 
Figure 5.4.1.c: FACS analyzed infected cells. A. After transfection, Flow Cytometry was used to 
collect the GFP-positive cells. The percentage of GFP-positive cells for each cell line is illustrated in the 
graphs. The wild type cell line was used as control. B. The pictures show U251 cell lines (U251 POU3f2 
ox, Blank vector, U251 POU3f2 siRNA and U251 scrambled siRNA) after transduction. Magnification is 
20x and Scale bar = 50µm. 
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Figure 5.4.1.d POU3f2 expression was checked by qRT-PCR and western blot in U251 cell lines. A. 
POU3f2 expression level was investigated in U251 WT, U251 POU3f2 ox, U251 blank vector, U251 
POU3f2 siRNA and U251 scrambled siRNA cell lines by qRT-PCR B. The rate of POU3f2 expression in 
U251 POU3f2 ox and U251 POU3f2 siRNA cell lines was checked by western blot. 
Figure 5.4.1.e Representative image of immunocytochemical staining using anti-POU3f2 in 
U251 cell lines. U251 Wild type, U251 POU3f2 ox and U251 POU3f2 siRNA cell lines are stained 
for POU3f2 by immunocytochemistry. POU3f2 staining (red) and nuclear counterstaining with DAPI 
(blue) as indicated. DAPI and POU3f2 staining is merged in the right panels, Scale bar = 50µm. 
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5.4.2 Proliferation assay 
In order to investigate whether POU3f2 expression impacts on cell growth we monitored cell 
growth in vitro for the U251 WT, U251 POU3f2 ox, U251 POU3f2 siRNA, and U251 
scrambled siRNA cell lines over 12 days. The proliferation assay was repeated two times for 
each cell line. Notably, the U251 POU3f2 ox cell line showed a higher growth rate with 
significantly higher cell numbers at day 9 and 12 (Fig 5.4.2). Between the other groups there 
were no significant differences (Fig 5.4.2). 
 
 
 
 
Figure 5.4.2 Representative data from a proliferation assay of U251 cell lines in vitro by manual 
counting. 15000 cells from different cell lines as indicated were seeded in each well and monitored 
until day 12. The U251 POU3f2 ox showed faster proliferation from day 9 in comparison to other 
cell lines. Error bars: SEM 
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5.4.3 Clonogenic assay 
We then compared clonogenicity between the genetically modified U251 cell lines. Thus, 
500 cells from each cell line were seeded in each well and cultured for 10 days. The cells 
were then stained, and the numbers of clones were counted. For the U251 POU3f2 ox (58 
colony) cell line the clones were both more numerous and bigger in size than for the other 
cell lines which displayed few clones that were hardly visible macroscopically (Fig 5.4.3).  
 
5.5 Animal experiment 
The U251 POU3f2 ox, U251 POU3f2 siRNA and U251 scrambled siRNA cell lines were 
also implanted into NOD-scid mice. Strikingly, all mice implanted with the U251 POU3f2 
ox cell line developed large tumors and succumbed to their disease within 110 days, whereas 
all mice in the other groups at that time were healthy (5.5 B). A PET was performed with a 
radioactively labeled thymidine tracer (
18
F)-FLT on one animal from each group at day 53 
after implantation and showed a distinct uptake only in the mouse implanted with U251 
POU3f2 ox, whereas uptake was barely detectable in mice from the other two groups (5.5 
A). The study was terminated 150 days after implantation, and mice with U251 scrambled 
siRNA or POU3f2 siRNA were then asymptomatic. 
 
Figure 5.4.3 Results of clonogenic assay for U251 cell lines. 500 cells were seeded for each cell line 
and plates were incubated in a normoxia incubator for 10 days. The number of the colony in the U251 
POU3f2 ox is significantly higher in compare to other cell lines.   
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Figure 5.5 Result of PET scan. A. A PET scan performed on day 53 and showed a tumor for the 
overexpresser group B.Survival in NOD-scid mice following implantation with different U251 cell 
lines as indicated. The experiment was terminated at day 150. Mice implanted with either U251 
POU3f2 siRNA or U251 scrambled siRNA were asymptomatic at this time point. 
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6. Discussion 
Innumerable studies have reported deregulation and re-expression of embryonic transcription 
factors in different types of cancers, including gliomas. Notably, various fetal transcription 
factors such as SOX2, SOX6, SOX11, Oct4 and Nanog have been linked to glioma 
progression
65,114,115,116,117
. In some publications, co-expression of several of these factors has 
been reported in gliomas. For instance, Guo et al. reported that Oct4, SOX2 and Nanog were 
simultaneously expressed in glioma samples
65
. Furthermore, expression levels were higher in 
grade III and IV compared to grade II tumors
65
. Since POU3f2 is a CNS specific fetal 
transcription factor, we therefore wanted to investigate its expression in a series of human 
glioma and possibly its correlation with tumor grade.  
6.1 Expression of POU3f2 in human glioma 
In this study, we found that POU3f2 were expressed in the large majority of gliomas, 
increasingly with tumor grade. Expression of POU3f2 in an adult brain has been reported by 
Xi He et al., in 1989
88
; POU3f2 expression in adult rat brain is moderate while its expression 
in embryonic rat is quite high
88
. Furthermore, our IHC data was confirmed with both western 
blotting and qPCR which strengthens our data. Although Schreiber et al. reported the 
expression of N-oct-3 (POU3f2) in gliomas, his series contained only 7 malignant gliomas 
and expression was only investigated using western blotting
118
. Thus, POU3f2 expression 
has not previously been validated in a larger panel of human gliomas of different histological 
subclasses and across various grades using complementary methods. However, POU3f2 
expression has been reported in melanomas 
119,120,69
, small cell lung cancer (SCLC)
97
 and 
Retinoblastoma (RB)
102
. Notably, both retinoblastoma
121
 and melanoma
122
 arise from cells of 
neuroectodermal origin, similar to glioma cells
123
. Overexpression of POU3f2 is linked to 
progression of melanoma, and its expression is upregulated 10-fold in human melanoma cell 
lines compared to normal melanocytes
124
. Others have reported that POU3f2 is highly 
expressed in melanoblasts and melanomas while it is dramatically decreased in normal 
melanocytes
125
. In women diagnosed with renal cell carcinoma, those with POU3f2-positive 
tumors had a poorer survival outcome than women with POU3f2-negative tumors, while no 
correlation of POU3f2 status with overall survival was demonstrated in men
126
. Thus, it is 
possible that POU3f2 may also have a role during tumor progression in gliomas. The 
increasing expression of POU3f2 with tumor grade also suggests that POU3f2 contributes to 
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tumor aggressiveness. Thus, to investigate the clinical significance of POU3f2, expression 
levels should also be correlated with patient survival.  
In this study, we used three different methods to investigate the expression of POU3f2. All 
methods showed that grade IV tumors expressed significantly higher levels of POU3f2 than 
at least one of the groups of lower grade tumors. However, whereas the IHC data showed 
significantly higher expression levels in grade IV tumors than both grade III and II tumors, 
western blotting showed higher expression in grade IV tumors only compared to grade II 
tumors and finally qPCR showed higher expression in grade IV tumors only compared to 
grade III tumors. Many factors may contribute to these findings. The most obvious reason is 
perhaps that these are different methods that measure expression by different criteria. 
Moreover, we did not have enough material to investigate the same samples with the three 
different methods. Thus, different samples were used for western blotting and qPCR and 
inter-individual variability between the patients may have contributed to our findings. It 
should be emphasized that the samples for the different analyses were picked randomly from 
the tumor bank before we knew result from any of the experiments. Thus, the selection of 
samples was not biased by knowledge of the POU3f2 expression from earlier analyses. 
Notably, the qPCR data differ from data obtained with the two other methods, as it showed 
higher expression (although not significant) in grade II than grade III tumors. However, the 
variability between the samples was much higher for the qPCR method, than for the other 
analyses. One possibility is that this variability reflects RNA degradation in some of the 
samples, since RNA is considerably more unstable than most proteins
127
. Thus, technical 
issues such as the quality of the samples may therefore also influence the results. In addition, 
transcription and translation is usually not linearly correlated, and posttranslational 
modifications may explain some of the observed discrepancy
128
.  Notably, many of these 
different post-transcriptional processes involving protein synthesis are not well understood. 
Secondly, proteins have a varying half-life in vivo as some degrade more easily
127
. Thirdly, 
ribosomal density compare to number of RNA molecules has an effect on translation 
process
128
. .  
Furthermore, different findings between the data from immunohistochemistry and western 
blotting may result from how these studies were designed. Usually, immunohistochemistry is 
considered a qualitative rather than a quantitative method. However, when staining is 
confined to the nucleus it is possible to estimate the labeling index for a sample based upon 
the fraction of immunopositive nuclei relative to all (immunopositive and –negative) nuceli. 
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This has proven useful for Ki67 staining of tumor sections as the Ki67 labelling index is a 
prognostic marker for certain cancer types. Since immunostaining was predominantly 
nuclear we therefore scored each section for its POU3f2 labelling index. However, this 
method does not take into account that some of the sections also displayed a cytoplasmic 
staining. In the western blot on the other hand, protein was extracted from the whole tissue 
and analysed.  Therefore, in IHC rate of positive cells was calculated by checking POU3f2 
expression in nucleus but in western blot cytoplasmic expression is also measured. 
6.2 Functional assays of POU3f2 
6.2.1 Proliferation assay 
Overexpression of POU3f2 increased proliferation in U251, similar to what has previously 
been reported in melanoma cell lines
119
. Moreover, overexpression of POU3f2 enhanced 
proliferation in melanocytes
120
. Conversely, earlier studies have reported that 
downregulation of POU3f2 in melanoma cells decreased proliferation
120
. In melanoma cell 
lines, POU3f2 expression is reportedly regulated by different pathways such as Wnt/beta-
catenin pathway, the RAS/RAF pathway, and the PI3K/AKT pathway
69
. Furthermore 
POU3f2 expression can be upregulated by amplification or modulation by miR-211 (in 
melanocytes)
69
. Upregulation and down-regulation of POU3f2 in SCLC cell lines and in 
melanoma increase and decrease proliferation activity respectively, albeit different 
mechanism is suggested for POU3f2 regulation in SCLC (Cobrinik et al., suggested that 
POU3f2 expression in SCLC is under control of the Rb gene) 
91
. Currently, little is known 
about how POU3f2 expression is regulated in gliomas. It is worth noting that reexpression of 
wild type retinoblastoma (Rb) protein in Y79 retinoblastoma cell line strongly decreased 
expression of the POU3f2
102
. Thus, the Rb protein may have a role in regulating POU3f2 
expression, which is disrupted in glioma and other cancers containing Rb mutations. It is 
important to point out that since we only have tested one glioma cell line so far, we do not 
know if POU3f2 consistently will increase proliferation in brain tumors. 
6.2.2 Colony formation assay 
Although cells divide during the observation period of a proliferation assay, they may still 
have a limited replicative potential. Thus, even among cancer cells there is only a fraction of 
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cells proliferating at a given time that have the ability to grow indefinitely. Clonogenic 
assays however, identifies cells giving rise to individual clones thereby reflecting potential 
for indefinite growth. Thus, we wanted to investigate whether POU3f2 also increased the 
clonogenicity of U251 cells in addition to proliferation. Therefore, we investigated the effect 
of overexpression and down-regulation of POU3f2 in a colony formation assay compared to 
various controls (U251 wild type and U251 scrambled siRNA). This experiment 
demonstrated that POU3f2 overexpression enhances clonogenicity, suggesting that the 
increased proliferation rates result from clonogenic cells and not only a number of transiently 
dividing cells. Furthermore, the other U251 cell lines formed small and poorly defined 
colonies. Because of this unconventional pattern of colony formation in the other cell lines 
and the fact that significant colony formation in the U251 POU3f2 overexpressor cell line 
was completely clear, plating efficiency was not calculated (Fig 5.4.3). Again, the limitation 
at this stage is the lack of confirmatory studies with additional glioma cell lines. However, 
similar experiments have recently been published but others who assessed the effects of 
forced overexpression of POU3f2 in differentiated glioblastoma cells (DGCs)
1
 that have lost 
their sphere formation ability
129
. Notably, they reported that overexpression of POU3f2 in 
DGCs restored their ability to form spheroid in approximately 3% of the cells (compared to 
0% for DCG expressing empty vector). Interestingly, co-expression of POU3f2 with 
SOX1/SOX2 enhanced spheroid formation even further, but was still not sufficient to 
mediate tumor formation in vivo
129
. 
6.2.3 Regional expression of POU3f2 
IHC demonstrated that POU3f2 was predominantly localised to the nucleus, which is 
expected, given its role as a transcription factor. Yet POU3f2 we also observed cytoplasmic 
expression. Previously, cytoplasmic localization of POU3f2 has been reported in mouse 
spinal cord (in E13.5) while in the ventricular and subventricular zones, POU3f2 was 
observed in the nucleus
130,131
. In melanoma cell lines, expression of POU3f2 was reportedly 
limited to the nucleus
132
 whereas cytoplasmic localization was observed in nevi. The authors 
suggested that this represented nucleocytoplasmic shuttling in melanocytic cells
68
. 
                                                          
1
 Differentiated glioblastoma cells derived from human tumor and grown as adherent monolayers in serum, and 
they are not able to initiate tumor formation in vivo
129
. 
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6.3 Effect of POU3f2 expression on glioma growth in vivo 
Since POU3f2 is widely expressed in human gliomas, increasingly with tumor grade, we 
reasoned it might have a role in brain tumor progression. Moreover, our studies in vitro 
suggested that POU3f2 could increase proliferation and clonogenicity. We therefore wanted 
to investigate how POU3f2 affected growth in vivo, and found that overexpression of 
POU3f2 dramatically increased growth of the U251 cell line, compared to controls (U251 
POU3f2 siRNA and U251 scrambled siRNA). Previously, Thomson et al., showed that 
human melanoma cell lines expressing antisense POU3f2 are not able to form tumors in 
immunodeficient mice
120,133
, Similarly, we found that U251 POU3f2 siRNA did not form 
tumors. In the animals engrafted with U251 scrambled siRNA and U251 wild type tumors 
formed like previously reported by others
134
. However, the experiment was terminated 
towards the end of my laboratory period and these sections are still under ongoing analysis.   
These results differ from those reported by Suva et al who did not find that overexpression of 
POU3f2 was sufficient to make DGCs tumorigenic in mice. In addition, when they co-
expressed POU3f2 with SOX2 and SALL2 these cells could still not form tumor. However, 
with a combined overexpression of four transcription factors, POU3f2, SOX2, SALL2 and 
OLIG2 DGCs were able to form the tumor in mice
129
. These 4 transcription factors were 
sufficent to reprogram DGCs into induced stem-like tumor propagating cells (iTPCs) while it 
showed same properites as TPCs
2
 (TPCs establised directly from human tumors)
129
. Since 
we found that overexpression of only POU3f2 was sufficient to significantly increased tumor 
formation it suggests that U251 may constitutively express additional factors necessary for 
tumor growth in vivo. Again, since we so far only have performed this study with one cell 
line, additional experiments are needed to conclude about the role of POU3f2 for tumor 
engraftment. Apart from, overexpressing POU3f2 in other cell lines, it is also important to 
investigate if cell lines that are tumorigenic when overexpressing POU3f2 also have a 
constitutive expression of other transcription factors in common. 
Conclusion: In this study, we showed that POU3f2 expression was expressed in the large 
majority in a series of human glioma samples. Expression of POU3f2 in gliomas was grade 
dependent, as the expression of POU3f2 increased from lower to higher grade.  
                                                          
2
 Stem-like tumor propagating cells are derived from human tumor and grow in serum-free, spherogenic 
culture. These cells can form a tumor in vivo. 
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We demonstrated that, the over expression of POU3f2 in the U251 glioma cell line 
significantly increased proliferation and colony formation. On the other hand down 
regulation of POU3f2 decrease colony formation, but did not show a significant effect on 
proliferation. 
In vivo experiment illustrated that overexpression of POU3f2 in U251 strongly promoted 
tumor growth, while knock-down abrogated the formation of macroscopically visible tumors 
upto 130 days after implantation. These data suggest that POU3f2 may play a pivotal role in 
glioma tumorigenesis, whereas the correlation with tumor grade may point to an involvement 
in glioma progression. We do not know whether it is a prognostic factor independent of 
tumor grade. 
7. Future perspective 
This study comprise both clinicopathological and functional data suggesting that the CNS 
specific fetal transcription POU3f2 may impact on multiple aspect of brain tumor growth and 
increase overall tumor aggressiveness. Due to the time constraints of this MSc project 
however, the functional data is limited to one glioma cell line. Further research should 
therefore expand these experiments to include additional glioma cell lines and preferably 
also primary tumor tissue. This way more extensive studies can be conducted both in vitro 
and in vivo and allow us to conclude with more certainty about the role of POU3f2 in brain 
tumor progression.  
Furthermore, we know little about how POU3f2 expression is regulated in glioma and about 
which signaling pathways that are activated downstream. Findings reported by other suggest 
that POU3f2 may work in a coordinated manner with other transcriptiona factors. 
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9. APPENDIX 
9.1 IHC staining for 51 samples of glioma with different grades 
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Figure 9.1 All the stained samples with IHC staining for grade II, III and IV:  Different grades stained 
against POU3f2 antibody. All the pictures are shown with 20x magnification, scale bar = 100µm; 
 
